# PT-141 (Bremelanotide): Sexual Health Research

**By TelosRX Editorial Team** · 2026-05-20

**PT-141 (bremelanotide) is a synthetic melanocortin peptide that acts on central nervous system pathways to support sexual desire and arousal. At [TelosRX](https://telosrx.com), access is subject to medical approval by a licensed provider through our asynchronous telehealth process.**

Interest in PT-141 has grown steadily as patients and clinicians seek non-hormonal options for sexual health. This guide covers the science, regulatory status, and how a telehealth evaluation works.

## What Is PT-141 (Bremelanotide)?

PT-141 is the research name for bremelanotide — a cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It binds to melanocortin receptors (MC3R and MC4R) in the central nervous system.

This central mechanism separates it from older sexual health therapies that rely on peripheral vascular effects.

## FDA Approval Status

Bremelanotide is commercially available as Vyleesi®, FDA-approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval applies to the branded commercial product under its specific indication only.

Compounded versions of PT-141 are **not FDA-approved**. They are prepared under federal compounding regulations and require a provider-issued prescription following individual patient evaluation.

## How PT-141 Differs from Conventional Options

PDE5 inhibitors (sildenafil, tadalafil) work by increasing blood flow to genital tissue. PT-141 acts upstream — at the brain level — to influence the desire pathway itself.

Feature

PT-141 (Bremelanotide)

PDE5 Inhibitors

Mechanism

Central (melanocortin receptors)

Peripheral (blood flow)

Addresses desire/arousal?

Yes

Primarily physical response

Hormonal?

No

No

FDA-approved commercial use

HSDD in premenopausal women (Vyleesi®)

Erectile dysfunction (multiple brands)

Route

Subcutaneous injection or intranasal

Oral tablet

## PT-141 for Women: What Clinical Data Shows

The pivotal trials supporting Vyleesi® enrolled premenopausal women with HSDD. Published data (Simon et al., _Obstetrics & Gynecology_, 2019) demonstrated statistically significant increases in satisfying sexual events and reductions in distress associated with low desire, compared with placebo.

Those findings reflect the FDA-approved commercial product under its approved indication. Compounded formulations have not been evaluated in the same trials.

## PT-141 for Men: Off-Label Research

Early clinical research has explored PT-141's effects on male sexual function. A study published in the _Journal of Sexual Medicine_ (Safarinejad & Hosseini, 2008) found bremelanotide associated with significant improvements in erectile function scores in men who had not responded to sildenafil.

This research is preliminary. Compounded PT-141 for men is not FDA-approved. Individual results vary.

## Who May Be a Candidate?

A licensed provider determines whether PT-141 is medically appropriate on a case-by-case basis. Patients who may initiate a discussion include:

-   Premenopausal women with persistent low sexual desire not explained by another medical condition
-   Men with low libido who have not responded to other interventions
-   Patients seeking a non-hormonal approach to sexual health
-   Individuals without uncontrolled hypertension (a contraindication noted in Vyleesi® labeling)

Approval is not guaranteed. A provider-issued prescription is required before any medication is dispensed.

## Safety Considerations

Across bremelanotide clinical trials, common adverse effects included nausea, flushing, and transient blood pressure increases. The Vyleesi® label includes a contraindication for patients with known cardiovascular disease.

Compounded formulations carry additional considerations. Potency, purity, and sterility depend on the compounding pharmacy's quality standards. Individual results vary.

## How the TelosRX Asynchronous Evaluation Works

TelosRX is an online-first, asynchronous telehealth service. No scheduled video appointment is required.

1.  Complete a detailed online intake form covering your health history and sexual health goals.
2.  A licensed provider reviews your submission and determines medical appropriateness.
3.  If approved, a prescription is issued and fulfilled through a licensed pharmacy.

The process happens on your schedule, at your pace.

* * *

_Compounded PT-141 is not FDA-approved. It is prepared under federal compounding regulations for individual patients. Approval is not guaranteed. Individual results vary. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service._

Start your private evaluation at [TelosRX](https://telosrx.com).

**Tags:** bremelanotide, HSDD, low libido, peptide therapy, PT-141, sexual health, telehealth

---

> Source: [Telos RX](https://www.telosrx.com/blogs/news/pt-141-bremelanotide-sexual-health-telehealth)